BioNTech's Gotistobart Data Nearly Doubles Survival Rates — Even as Sahin Keeps Selling
Published on 09/17/2026 at 19:01 | Editorial boerse-global.de
BioNTech has delivered updated Phase 3 results for its cancer drug Gotistobart in a specific form of non-small cell lung cancer, and the numbers are turning heads. Survival rates in the PRESERVE-003 study nearly doubled in the new analysis, sending the stock up 3.2% to EUR 86.25 in today's session.
The jump extends a pattern of upbeat market reactions to oncology readouts from the Mainz-based company. The first presentation of the lung cancer data had already stirred the shares; the refreshed analysis now confirms the trend with an even more striking figure. For investors who have grown used to seeing BioNTech through the lens of management selling pressure, the study offers something more tangible: hard clinical evidence.
A Pipeline Beyond Vaccines
Gotistobart is central to BioNTech's push to broaden its portfolio beyond the COVID-19 vaccine franchise. The latest Phase 3 results in squamous non-small cell lung cancer back up that ambition — the near-doubling of survival rates in the current evaluation is being read as a clear demonstration of efficacy in a tumor type that is notoriously difficult to treat. That puts the drug squarely in the spotlight for shareholders assessing BioNTech's future once the shrinking vaccine business is stripped out of the equation.
The market's response underscores just how sensitive investors have become to oncology news out of Mainz. After months dominated by headlines about declining Comirnaty revenues and insider sales by CEO Ugur Sahin, the study provides a counterweight: concrete clinical substance rather than pure expectation.
Skepticism Hasn't Vanished
Not everyone is fully on board. One analyst house cited a faster-than-expected erosion of the Pfizer partnership on Comirnaty, the absence of de-risking data for the drug candidate Pumitamig before 2028, and muted expectations for the mRNA-based iNeST program as reasons for caution.
Should investors sell immediately? Or is it worth buying BioNTech?
That assessment predates the Gotistobart data now on the table and will likely force analysts to revisit their models in the coming weeks. For the moment, though, the market is showing that positive oncology news carries more weight than the earlier skepticism surrounding the vaccine business. Today's gain also stabilizes the short-term trend after the weaker stretch since the March low. Whether the recovery holds will depend heavily on how robust the Gotistobart data proves in further analyses and regulatory discussions.
The CEO's Steady Selling
While the science grabs the spotlight, a quieter story has been unfolding in BioNTech's filings. On September 15, Sahin sold 34,000 shares at USD 96.49, followed by another 15,000 shares at USD 96.09 the next day. That fits into a longer chain: 45,000 and 41,000 shares in early September, 20,500 before that, and then two more batches of roughly 36,000 to 37,000 shares each.
Every one of those transactions was executed under an automated trading plan set up back in June, according to the disclosures filed with the U.S. securities regulator. Formally, a Rule 10b5-1 plan means the sales aren't made spontaneously on the basis of current knowledge but follow a pre-arranged schedule — a structure meant to inspire confidence.
Yet the sheer regularity — week after week, almost like clockwork — raises a question about how much a founder-CEO still ties himself to his company when he is systematically parting with shares while promising oncology data is being presented. That simultaneity is what stands out. The stock reacted to the data with a gain of 0.8% and now trades at EUR 84.30. Read one way, it's a vote of confidence: the market believes in the pipeline, regardless of what the CEO does with his personal holdings.
A Tension the Whole Sector Knows
Still, a contradiction persists that reaches beyond BioNTech. The entire biotech industry lives in this tension: enormous scientific promises on one side, sober capital-market logic on the other. Companies like BioNTech must invest in research for years before it becomes clear whether a therapy actually works — while their share prices move to the rhythm of conference data, approval decisions, and insider transactions.
The stock itself mirrors that split personality. The picture has clouded over since, with intermittent hope flickering through the oncology pipeline. Against that backdrop, the founder's steady selling looks like one more data point investors can hardly ignore, even if it formally says nothing about future prospects.
What remains is an observation without an easy answer. Sahin co-founded BioNTech and shaped it profoundly; his stake is likely to remain substantial even after these sales. Even so, the question running through the entire growth sector is worth asking: how much equity conviction can one reasonably expect from founders when even they are visibly cashing in while the real test of the medicines is still ahead? The calendar provides the answer — only when solid data from later-stage trials arrives will it become clear whether the current market skepticism was justified, or whether the pipeline's substance ultimately wins out.
Ad
BioNTech Stock: New Analysis - 17 September
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
